Natroba topical suspension approved for head lice treatment

NATROBA (spinosad) 0.9% topical suspension by Pernix Therapeutics and ParaPRO
NATROBA (spinosad) 0.9% topical suspension by Pernix Therapeutics and ParaPRO
The FDA has approved Natroba (spinosad, from ParaPRO) topical suspension 0.9% for the treatment of head lice infestations in patients ≥4 years old. This approval was based on data from two multicenter, randomized, active-controlled studies conducted in a total of 552 patients. Patients received a 10-minute treatment with Natroba. If live lice were seen a week later, a second treatment was applied. The proportion of subjects who were lice-free 14 days after the final treatment of Natroba was approximately 86% compared to 44% of the control group.  

For more information visit www.parapro.com.